Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Blood (2022) 140 (Supplement 1): 276–278.

DOI: https://doi.org/10.1182/blood-2022-163340

Published: 2022

Journal Articles

Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al. , Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Alexandre Iat, Michael Loschi, Sami Benachour, Anne Calleja, Edmond Chiche, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Patricia Brugel, Lea Ryffel, Laurène Fenwarth, Alice Marceau, Elise Fournier, Berengere Dadone, Thomas Cluzeau

Blood (2022) 140 (Supplement 1): 9105–9106.

DOI: https://doi.org/10.1182/blood-2022-164583

Published: 2022

Journal Articles

Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS

Raynier Devillier, Edouard Forcade, Jacques-Olivier Bay, Anne Huynh, Anna Berceanu, Régis Peffault de Latour, Claude-Eric Bulabois, Mohamad Mohty, Michael Loschi, Emmanuelle Tavernier, Micha Srour, Patrice Chevallier, Amandine Charbonnier, Aline Schmidt, Didier Blaise

Blood (2022) 140 (Supplement 1): 2381–2382.

DOI: https://doi.org/10.1182/blood-2022-164511

Published: 2022

Journal Articles

Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia

Bochra Sedaki, Alexandre Iat, Michael Loschi, Sami Benachour, Edmond Chiche, Lea Ryffel, Patricia Brugel, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Berengere Dadone, Thomas Cluzeau

Blood (2022) 140 (Supplement 1): 11718–11719.

DOI: https://doi.org/10.1182/blood-2022-164608

Published: 2022

Journal Articles

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 1859–1861.

DOI: https://doi.org/10.1182/blood-2022-167840

Published: 2022

Journal Articles

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière Wallet, Amandine Le Bourgeois, Maud D'Aveni, Anne Huynh, Ana Berceanu, Tony Marchand, Sylvain Chantepie, Carmen Botella Garcia, Michael Loschi, Magalie Joris, Cristina Castilla-Llorente, Anne Thiebaut-Bertrand, Sylvie François, Mathieu Leclerc, Patrice Chevallier, Stephanie Nguyen

Blood (2022) 139 (1): 134–137.

DOI: https://doi.org/10.1182/blood.2021014232

Published: 2022

Includes: Supplemental data

Journal Articles

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière, Amandine Le Bourgeois, Maud d'Aveni, Anna Berceanu, Sylvain Chantepie, Carmen Botella, Michael Loschi, Magalie Joris, Cristina Castilla-Llorente, Sylvie Francois, Mathieu Leclerc, Patrice Chevallier, Stephanie Nguyen Quoc

Blood (2021) 138 (Supplement 1): 336.

DOI: https://doi.org/10.1182/blood-2021-149495

Published: 2021

Journal Articles

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Blood (2021) 138 (Supplement 1): 262.

DOI: https://doi.org/10.1182/blood-2021-147709

Published: 2021

Journal Articles

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Nicola Vianelli, Giulia Benevolo, Alessandro Vannucchi, Claire N. Harrison, Michael Loschi, Haifa Kathrin Al-Ali, Massimiliano Bonifacio, Francisco Cervantes, Tomasz Wrobel, Giovanni Barosi, Jean-Jaques Kiladjian, Srdan Verstovsek, Ruben A. Mesa, Shelonitda Rose, Vishwanath Gharpure, Christopher Hernandez, Jun Zhang, Francesco Passamonti

Blood (2021) 138 (Supplement 1): 3643.

DOI: https://doi.org/10.1182/blood-2021-147614

Published: 2021

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adults with Primary Mediastinal B Cells Lymphoma (PMBCL): A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) Group

Blood (2021) 138 (Supplement 1): 1826.

DOI: https://doi.org/10.1182/blood-2021-146857

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood (2021) 138 (Supplement 1): 1842.

DOI: https://doi.org/10.1182/blood-2021-146846

Published: 2021

Journal Articles

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Sara Villar, Sylvie Chevret, Xavier Poire, Amandine Charbonnier, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Yves Beguin, Stephanie Nguyen, Marie Robin

Blood (2021) 138 (Supplement 1): 1844.

DOI: https://doi.org/10.1182/blood-2021-146380

Published: 2021

Journal Articles

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Blood (2021) 137 (8): 1090–1103.

DOI: https://doi.org/10.1182/blood.2020005628

Published: 2021

Includes: Supplemental data

Journal Articles

Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study

Alienor Xhaard, MD, Constance Xhaard, Maud D'Aveni, MD, Hélène Salvator, MD PhD, Marie-Laure Chabi-Charvillat, MD, Tereza Coman, MD PhD, Yves Beguin, MD PhD, Yves Chalandon, MD, Xavier Poire, MD, Michael Loschi, MD PhD, Catherine Paillard, MD PhD, Bénédicte Bruno, MD, Patrice Ceballos, MD PhD, Jean-Hugues Dalle, MD PhD, Karin Bilger, MD, Jacques-Olivier Bay, MD PhD, Marie Robin, MD PhD, Stephanie N'guyen-Quoc, MD PhD, Marie Thérèse Rubio, MD PhD

Blood (2020) 136 (Supplement 1): 34.

DOI: https://doi.org/10.1182/blood-2020-138411

Published: 2020

Journal Articles

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

Florent Malard, MDPhD, Michael Loschi, MD PhD, Faezeh Legrand, MD, Raynier Devillier, Sarah Guenounou, MD, Cecile Borel, MD, Deborah Desmier, MD, Jérôme Cornillon, MD, Amandine Le Bourgeois, MD, Jean-Baptiste Mear, MD, Delphine Martineau, MD, Hélène Labussière, MD, Marie-Anne Couturier, MD, Claude-Eric Bulabois, MD, Emilie Plantamura, PhD PharmD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 15.

DOI: https://doi.org/10.1182/blood-2020-136604

Published: 2020

Journal Articles

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Blood (2020) 135 (1): 28–40.

DOI: https://doi.org/10.1182/blood.2019000032

Published: 2020

Includes: Supplemental data

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

DOI: https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD

Blood (2019) 134 (19): 1670–1682.

DOI: https://doi.org/10.1182/blood.2019001950

Published: 2019

Journal Articles

ST2 and ROR-γ-t Roles in Intestinal Regulatory T Cells

Jinfeng Yang, PhD, Abdulraouf Ramadan, PhD, Dawn Reichenbach, PhD, Michael Loschi, MD, Jilu Zhang, PhD, Brad Griesenauer, PhD, Hong Liu, MS, Keli Lee Hippen, PhD, Bruce R. Blazar, MD, Sophie Paczesny, MD PhD

Blood (2018) 132 (Supplement 1): 66.

DOI: https://doi.org/10.1182/blood-2018-99-113003

Published: 2018

Journal Articles

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

Blood (2017) 129 (18): 2570–2580.

DOI: https://doi.org/10.1182/blood-2017-01-758854

Published: 2017

Includes: Supplemental data

NARROW

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al. , Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS

Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adults with Primary Mediastinal B Cells Lymphoma (PMBCL): A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) Group

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD

ST2 and ROR-γ-t Roles in Intestinal Regulatory T Cells

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only